title: Cutting edge: loss of α4 integrin expression differentially affects the homing of Th1 and Th17 cells.
abstract: The neutralization of α4 integrin is currently used as treatment in several autoimmune diseases and is thought to prevent the entry of most immune cells in target tissues. In this study, we showed that selective deletion of α4 integrin in T cells did not prevent but delayed the development of experimental autoimmune encephalomyelitis. Whereas both Th1 and Th17 cells infiltrate the CNS of wild-type mice, T cells present in the CNS of mice lacking α4 integrin were mainly enriched in Th17 cells, suggesting that this T cell subset uses other integrins to access the CNS. In contrast, α4 integrin expression is important for Th1 cells to enter the CNS and for the stability of their Th1-associated genetic program. Therefore, our data suggest that anti-α4 integrin Ab treatment may be more efficient in the treatment of Th1- rather than Th17-mediated disease.
authors.affiliation: Immunology Program, Benaroya Research Institute, Seattle, WA 98101, USA.
authors.forename: Simon
authors.initials: S
authors.lastname: Glatigny
authors.forename: Rebekka
authors.initials: R
authors.lastname: Duhen
authors.forename: Mohamed
authors.initials: M
authors.lastname: Oukka
authors.forename: Estelle
authors.initials: E
authors.lastname: Bettelli
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D002464:Cell Migration Inhibition / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000235:genetics / Q000276:immunology / Q000473:pathology; D017353:Gene Deletion; D005786:Gene Expression Regulation / Q000276:immunology*; D039441:Integrin alpha4 / Q000096:biosynthesis / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D058504:Th17 Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
chemical_list: D039441:Integrin alpha4
references.citation: N Engl J Med. 2007 Jun 21;356(25):2622-9
references.pmid: 17582072
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11058-63
references.pmid: 15263094
references.citation: Biochim Biophys Acta. 2011 Feb;1812(2):246-51
references.pmid: 20600875
references.citation: J Immunol. 1995 Sep 15;155(6):2938-47
references.pmid: 7673711
references.citation: Ann Neurol. 2006 May;59(5):748-54
references.pmid: 16634035
references.citation: Cell. 2002 Sep 20;110(6):673-87
references.pmid: 12297042
references.citation: Nature. 1992 Mar 5;356(6364):63-6
references.pmid: 1538783
references.citation: Nature. 2008 Jun 19;453(7198):1051-7
references.pmid: 18563156
references.citation: Brain. 2009 Dec;132(Pt 12):3329-41
references.pmid: 19933767
references.citation: J Clin Invest. 2001 Apr;107(8):995-1006
references.pmid: 11306603
references.citation: Nature. 2006 May 11;441(7090):235-8
references.pmid: 16648838
references.citation: Nat Med. 2010 Apr;16(4):406-12
references.pmid: 20348925
references.citation: Clin Exp Immunol. 2010 Oct;162(1):1-11
references.pmid: 20682002
references.citation: Nat Immunol. 2011 Mar;12(3):255-63
references.pmid: 21278737
references.citation: J Immunol. 2006 May 15;176(10):6225-34
references.pmid: 16670333
references.citation: Annu Rev Immunol. 2005;23:683-747
references.pmid: 15771584
references.citation: Eur J Immunol. 2011 Mar;41(3):813-21
references.pmid: 21341265
references.citation: J Clin Invest. 1998 Dec 15;102(12):2096-105
references.pmid: 9854045
references.citation: Mol Cell Biol. 2003 Dec;23(24):9349-60
references.pmid: 14645544